Posner-Schlossman Syndrome
Conditions
Interventions
Conventional Treatment Group:IOP-lowering medication(1) When the patient's intraocular pressure is higher than 35mmHg, intravenously inject 20% mannitol once, and combine with more than 2 kinds of top
2) The patient' IOP is higher than 21mmHg but not higher than 35mmHg, use a local intraocular pressure lowering
Conventional Treatment Group:Anti-inflammation medication(No KP, no steriods
with KP, Prednisolone Acetate Eye Drops tid)
New Treatment Group:IOP-lowering medication(the same as conventional group)
New Treatment Group:Anti-inflammation medication(1) mutton-fat Kp should be treated with topical steriods based on Prednisolone Acetate Eye Drops tid
2) coin-shaped Kp should be treated with 2% ganciclovir eye drops, qid
3) When there is old or pigmented Kp, do not use steriods for treatment)
New Treatment Group:Lifestyle improvement
when the cup-disk ratio is too large and neurological damage occurs, add intraocular pressure lowering drugs
when the corneal endothelial cell count of the affected eye is more than 10% compared to the contralateral eye, it is recommended to add 2% ganciclovir drops Eye drops
Sponsors
Eye & ENT Hospital of Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Recurrent intraocular pressure (IOP) increase and each time > 21mmHg; IOP between attacks is normal, with no or mild anterior chamber inflammation, Kp can be seen under the slit-lamp biomicroscopy, no post-pupill synechiae, open chamber angle; the IOP, visual field and optic disc of the non-affected eye are all normal; 2) Aged >= 18 years; 3) Sign informed consent and agree to be selected.
Exclusion criteria
Exclusion criteria: 1) Suffering from primary glaucoma or increased intraocular pressure caused by other known causes; 2) Pre-existing other eye diseases including ocular trauma, retinal disease, corneal disease or inflammation; 3) The patient had received anti-glaucoma surgery before enrollment; 4) Those who are allergic to treatment drugs including steriods, IOP-lowering drugs or ganciclovir; 5) Existence of liver and kidney dysfunction or blood system diseases; 6) Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraocular pressure;Keratic precipitate;Anterior chamber cell;Tyndall reaction;Best corrected visual acuity;Pupil diameter;Cup-disc ratio;Lens turbidity;Iris depigmentation;Visual field;Corneal endothelium count;Blood cytomegalovirus antibody;Blood cytomegalovirus nucleic acid amplification testing;Aqueous humor cytomegalovirus antibody;Aqueous humor cytomegalovirus nucleic acid amplification testing; | — |
Countries
China
Contacts
Public ContactXiangmei Kong
Eye & ENT Hospital of Fudan University
Outcome results
None listed